257 related articles for article (PubMed ID: 25310855)
21. Relevance of pelvic and para-aortic node metastases in early-stage ovarian cancer.
Bachmann C; Krämer B; Brucker SY; Stäbler A; Fend F; Wallwiener D; Grischke EM; Rothmund R
Anticancer Res; 2014 Nov; 34(11):6735-8. PubMed ID: 25368283
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma.
Mahdi H; Moslemi-Kebria M; Levinson KL; Gojayev A; Lockhart D; Ali-Fehmi R; Munkarah AR
Int J Gynecol Cancer; 2013 Sep; 23(7):1226-30. PubMed ID: 23736258
[TBL] [Abstract][Full Text] [Related]
23. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GA; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):186-9. PubMed ID: 17688926
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.
Zhou J; He ZY; Li FY; Sun JY; Lin HX; Wu SG; Chen QH
Oncotarget; 2016 Feb; 7(7):7952-9. PubMed ID: 26788911
[TBL] [Abstract][Full Text] [Related]
25. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors.
Takeshima N; Hirai Y; Umayahara K; Fujiwara K; Takizawa K; Hasumi K
Gynecol Oncol; 2005 Nov; 99(2):427-31. PubMed ID: 16112718
[TBL] [Abstract][Full Text] [Related]
26. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.
Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M
Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052
[TBL] [Abstract][Full Text] [Related]
27. Contemporary analysis of pelvic and para-aortic metastasis in endometrial cancer using the SEER registry.
Katsoulakis E; Mattes MD; Rineer JM; Nabhani T; Mourad WF; Choi K; Schreiber D
Int J Gynaecol Obstet; 2014 Dec; 127(3):293-6. PubMed ID: 25194213
[TBL] [Abstract][Full Text] [Related]
28. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract][Full Text] [Related]
29. Incidence and Pattern of Spread of Lymph Node Metastasis in Patients With Low-grade Serous Ovarian Cancer.
Wafa M; Braicu EI; Muallem MZ; Richter R; Taube E; Sehouli J; Grabowski JP
Anticancer Res; 2019 Oct; 39(10):5617-5621. PubMed ID: 31570458
[TBL] [Abstract][Full Text] [Related]
30. Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer?
Roger N; Zafrani Y; Uzan C; Gouy S; Rey A; Pautier P; Lhommé C; Duvillard P; Castaigne D; Morice P
Ann Surg Oncol; 2008 Jan; 15(1):333-8. PubMed ID: 17943386
[TBL] [Abstract][Full Text] [Related]
31. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy.
Mehta N; Yamada SD; Rotmensch J; Mundt AJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1004-9. PubMed ID: 14575831
[TBL] [Abstract][Full Text] [Related]
32. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
[TBL] [Abstract][Full Text] [Related]
33. Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment.
Del Carmen MG; Pareja R; Melamed A; Rodriguez J; Greer A; Clark RM; Rice LW
Gynecol Oncol; 2018 Sep; 150(3):406-411. PubMed ID: 30017539
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive lymphadenectomy and survival prediction in uterine serous cancer patients after surgery: A population-based analysis.
Li H; Xie X; Liu Y; Huang X; Lin H; Li J; Lin Z
Eur J Surg Oncol; 2020 Jul; 46(7):1339-1346. PubMed ID: 32402510
[TBL] [Abstract][Full Text] [Related]
35. Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants.
Garg G; Kruger M; Christensen C; Deppe G; Toy EP
Int J Gynecol Cancer; 2011 Dec; 21(9):1606-12. PubMed ID: 21720252
[TBL] [Abstract][Full Text] [Related]
36. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival.
Bristow RE; Zahurak ML; Alexander CJ; Zellars RC; Montz FJ
Int J Gynecol Cancer; 2003; 13(5):664-72. PubMed ID: 14675352
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
van Kol KGG; Ebisch RMF; van der Aa M; Wenzel HB; Piek JMJ; Bekkers RLM
Gynecol Oncol; 2023 Apr; 171():9-14. PubMed ID: 36804623
[TBL] [Abstract][Full Text] [Related]
38. The risk of subsequent malignancies in women with uterine papillary serous or clear cell endometrial cancers.
Hinshaw HD; Smith A; Rungruang B; Kelley JL; Beriwal S; Krivak TC; Sukumvanich P; Olawaiye AB
Int J Gynecol Cancer; 2013 Jul; 23(6):1044-9. PubMed ID: 23748174
[TBL] [Abstract][Full Text] [Related]
39. Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection.
Lea JS; Sheets EE; Duska LR; Miller DS; Schorge JO
Gynecol Oncol; 2002 Feb; 84(2):285-8. PubMed ID: 11812088
[TBL] [Abstract][Full Text] [Related]
40. Para-aortic lymph node involvement revisited in the light of the revised 2018 FIGO staging system for cervical cancer.
Ayhan A; Aslan K; Öz M; Tohma YA; Kuşçu E; Meydanli MM
Arch Gynecol Obstet; 2019 Sep; 300(3):675-682. PubMed ID: 31263988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
